Published in Lupus on January 01, 2001
Customized molecular phenotyping by quantitative gene expression and pattern recognition analysis. Genome Res (2003) 1.79
Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest (2003) 1.63
Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. J Exp Med (2009) 1.19
Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis (2004) 1.13
Effect of oestrogen on T cell apoptosis in patients with systemic lupus erythematosus. Clin Exp Immunol (2010) 0.99
The role of apoptosis proteins and complement components in the etiopathogenesis of systemic lupus erythematosus. Clinics (Sao Paulo) (2010) 0.92
Initiation but no execution - modulation of peripheral blood lymphocyte apoptosis in rheumatoid arthritis - a potential role for heat shock protein 70. J Inflamm (Lond) (2011) 0.91
Stronger Correlation between Interleukin 18 and Soluble Fas in Lupus Nephritis Compared with Mild Lupus. ISRN Rheumatol (2013) 0.83
Interaction between glutathione and apoptosis in systemic lupus erythematosus. Autoimmun Rev (2012) 0.83
Increased Tim-3 expression on peripheral T lymphocyte subsets and association with higher disease activity in systemic lupus erythematosus. Diagn Pathol (2015) 0.80
Peripheral blood lymphocyte apoptosis and circulating dendritic cells in patients with systemic lupus erythematosus: correlation with immunological status and disease-related symptoms. Clin Rheumatol (2006) 0.80
The type of responder T-cell has a significant impact in a human in vitro suppression assay. PLoS One (2010) 0.79
An antibody-based leukocyte-capture microarray for the diagnosis of systemic lupus erythematosus. PLoS One (2013) 0.77
A tolerogenic peptide down-regulates mature B cells in bone marrow of lupus-afflicted mice by inhibition of interleukin-7, leading to apoptosis. Immunology (2009) 0.77
Association of FAS gene polymorphisms with systemic lupus erythematosus: A case-control study and meta-analysis. Exp Ther Med (2012) 0.77
The expression of TLR-9, CD86, and CD95 phenotypes in circulating B cells of patients with chronic viral hepatitis B or C before and after antiviral therapy. Mediators Inflamm (2015) 0.75
Correlation of CD95 and soluble CD95 expression with acute rejection status of liver transplantation. World J Gastroenterol (2005) 0.75
Analysis of CD95 and CCR7 expression on circulating CD4(+) lymphocytes revealed disparate immunoregulatory potentials in systemic lupus erythematosus. Saudi J Biol Sci (2015) 0.75
Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum (1994) 14.16
Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med (1996) 4.18
Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol (1994) 3.50
Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum (1990) 3.37
Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest (1989) 3.34
Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med (1994) 2.62
Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum (1990) 2.24
Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med (2000) 2.19
Vitamin E status during dietary fish oil supplementation in rheumatoid arthritis. Arthritis Rheum (1990) 2.14
Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet (1990) 2.12
[Sjögren's disease]. Ned Tijdschr Geneeskd (1994) 2.00
The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med (2001) 1.89
Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process. Clin Exp Immunol (1994) 1.85
Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. Kidney Int (2000) 1.81
Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum (1995) 1.80
Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int (1990) 1.77
IgM, IgA, and IgG rheumatoid factors in early rheumatoid arthritis predictive of radiological progression? Scand J Rheumatol (1995) 1.76
The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun (1988) 1.76
Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum (2000) 1.74
Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide. J Rheumatol (1993) 1.71
Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1. Relation to clinical parameters in 250 patients. J Neurol Sci (1983) 1.69
Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders. Clin Exp Immunol (1991) 1.69
Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. Kidney Int (1994) 1.66
Antimyeloperoxidase-associated proliferative glomerulonephritis: an animal model. J Exp Med (1993) 1.63
Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol (1999) 1.62
Skin sensitivity to UVB irradiation in systemic lupus erythematosus is not related to the level of apoptosis induction in keratinocytes. Rheumatology (Oxford) (2005) 1.59
In vivo IgA coating of anaerobic bacteria in human faeces. Gut (1996) 1.55
Scl-86, a marker antigen for diffuse scleroderma. J Clin Invest (1985) 1.43
Co-trimoxazole and Wegener's granulomatosis: more than a coincidence? Nephrol Dial Transplant (1997) 1.43
Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology (1993) 1.41
Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol (2001) 1.41
Direct flow cytometry of anaerobic bacteria in human feces. Cytometry (1994) 1.41
[The role of perinuclear antineutrophil granulocytes cytoplasmic antibodies in the diagnosis of vasculitis and chronic inflammatory diseases]. Ned Tijdschr Geneeskd (1996) 1.40
Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis (1982) 1.39
Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis (2004) 1.38
Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta (1991) 1.38
Leukocyte activation in sepsis; correlations with disease state and mortality. Intensive Care Med (2000) 1.38
Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat. Am J Pathol (1996) 1.37
Increased frequency of B8/DR3 in scleroderma and association of the haplotype with impaired cellular immune response. Clin Exp Immunol (1981) 1.34
Cutaneous reactions to captopril. Predictive value of skin tests. Clin Allergy (1984) 1.34
Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol (1997) 1.34
The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol (1993) 1.33
Rapid automated enzyme immunoassay of serum amyloid A. Clin Chem (1994) 1.31
Monocyte activation in patients with Wegener's granulomatosis. Ann Rheum Dis (1999) 1.31
Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis (1995) 1.29
Systemic involvement and immunologic findings in patients presenting with Raynaud's phenomenon. Am J Med (1980) 1.28
Absence of cross-reactivity between captopril and enalapril. Lancet (1984) 1.24
Immune-complex glomerulopathy in patients treated with captopril. Lancet (1980) 1.23
B cell activity in systemic lupus erythematosus: depressed in vivo humoral immune response to a primary antigen (haemocyanin) and increased in vitro spontaneous immunoglobulin synthesis. Clin Exp Immunol (1983) 1.22
Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus (2006) 1.20
Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood (1995) 1.19
Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood (1994) 1.16
Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Immunol (1994) 1.15
Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis (2001) 1.14
C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol (1990) 1.14
Patients with systemic lupus erythematosus and Jaccoud's arthropathy: a clinical subset with an increased C reactive protein response? Ann Rheum Dis (1992) 1.13
Effects of fish oil supplementation in rheumatoid arthritis. Ann Rheum Dis (1990) 1.13
Serum markers of T cell activation in relapses of Wegener's granulomatosis. Clin Exp Immunol (1993) 1.13
Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity? Clin Exp Immunol (1992) 1.13
Lack of endothelial nitric oxide synthase aggravates murine accelerated anti-glomerular basement membrane glomerulonephritis. Am J Pathol (2000) 1.13
Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates. Clin Exp Immunol (1994) 1.12
HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions development. Autoimmun Rev (2010) 1.12
HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis. Autoimmun Rev (2012) 1.12
Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. Kidney Int (1998) 1.11
Detection of autoantibodies against myeloid lysosomal enzymes: a useful adjunct to classification of patients with biopsy-proven necrotizing arteritis. Am J Med (1991) 1.11
Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis (2005) 1.09
Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon. J Rheumatol (1983) 1.09
Antineutrophil cytoplasmic antibodies in rheumatoid arthritis. Characterization and clinical correlations. Arthritis Rheum (1993) 1.09
Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods (1996) 1.08
Opposed independent effects and epistasis in the complex association of IRF5 to SLE. Genes Immun (2007) 1.08
Proteinase 3, Wegener's autoantigen: from gene to antigen. J Leukoc Biol (2001) 1.08
Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis (2005) 1.08
Sialometry and sialochemistry: diagnostic tools for Sjögren's syndrome. Ann Rheum Dis (2001) 1.07
B cell activation in clinically quiescent systemic lupus erythematosus (SLE) is related to immunoglobulin levels, but not to levels of anti-dsDNA, nor to concurrent T cell activation. Clin Exp Immunol (1993) 1.07
Reticuloendothelial Fc receptor function in SLE patients. I. Primary HLA linked defect or acquired dysfunction secondary to disease activity? Clin Exp Immunol (1984) 1.07
Leucocyte membrane expression of proteinase 3 correlates with disease activity in patients with Wegener's granulomatosis. Br J Rheumatol (1998) 1.07